The New England Journal of Medicine, ISSN 0028-4793, 02/2014, Volume 370, Issue 8, pp. 699 - 708
The addition of bevacizumab to temozolomide and radiotherapy did not improve overall survival in patients with glioblastoma. Patients receiving bevacizumab had...
MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | GLIOMA | RECURRENT GLIOBLASTOMA | PHASE-III | CLINICAL-TRIALS | VALIDATION | COMBINATION | MULTIFORME | ADJUVANT TEMOZOLOMIDE | RADIATION-THERAPY | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Dacarbazine - therapeutic use | Humans | Proportional Hazards Models | Combined Modality Therapy | Brain Neoplasms - drug therapy | Glioblastoma - radiotherapy | Bevacizumab | Disease-Free Survival | Dacarbazine - analogs & derivatives | Survival Analysis | Angiogenesis Inhibitors - therapeutic use | Adult | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Angiogenesis Inhibitors - adverse effects | Glioblastoma - mortality | Drug therapy | Glioblastoma multiforme | Research | Nuclear magnetic resonance--NMR | Medical imaging | Glioblastoma | Cognition | Radiation therapy | Cancer therapies | Survival | Patients | Quality of life | Angiogenesis | Chemotherapy | Intestine | Monoclonal antibodies | Ligands | Death | Temozolomide | Thromboembolism | Vascular endothelial growth factor | Neutropenia
MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | GLIOMA | RECURRENT GLIOBLASTOMA | PHASE-III | CLINICAL-TRIALS | VALIDATION | COMBINATION | MULTIFORME | ADJUVANT TEMOZOLOMIDE | RADIATION-THERAPY | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Dacarbazine - therapeutic use | Humans | Proportional Hazards Models | Combined Modality Therapy | Brain Neoplasms - drug therapy | Glioblastoma - radiotherapy | Bevacizumab | Disease-Free Survival | Dacarbazine - analogs & derivatives | Survival Analysis | Angiogenesis Inhibitors - therapeutic use | Adult | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Angiogenesis Inhibitors - adverse effects | Glioblastoma - mortality | Drug therapy | Glioblastoma multiforme | Research | Nuclear magnetic resonance--NMR | Medical imaging | Glioblastoma | Cognition | Radiation therapy | Cancer therapies | Survival | Patients | Quality of life | Angiogenesis | Chemotherapy | Intestine | Monoclonal antibodies | Ligands | Death | Temozolomide | Thromboembolism | Vascular endothelial growth factor | Neutropenia
Journal Article
AIDS Research and Human Retroviruses, ISSN 0889-2229, 10/2016, Volume 32, Issue S1, pp. 1 - 409
Journal Article
1981, A Wiley medical publication, ISBN 9780471055204, xv, 718 p., [1] leaf of plates
Book
Journal of Clinical Oncology, ISSN 0732-183X, 11/2013, Volume 31, Issue 32, pp. 4085 - 4091
Purpose Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O6-methylguanine-DNA...
MALIGNANT GLIOMA | INACTIVATION | THERAPY | ONCOLOGY | RECURRENT | MGMT | VALIDATION | COMBINATION | CANCER | Dacarbazine - administration & dosage | Dacarbazine - adverse effects | Humans | Middle Aged | DNA Repair Enzymes - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | DNA Methylation | DNA Modification Methylases - genetics | Glioblastoma - genetics | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Female | Aged | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Index Medicus | Original Reports | Neur7 | Neur1
MALIGNANT GLIOMA | INACTIVATION | THERAPY | ONCOLOGY | RECURRENT | MGMT | VALIDATION | COMBINATION | CANCER | Dacarbazine - administration & dosage | Dacarbazine - adverse effects | Humans | Middle Aged | DNA Repair Enzymes - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | DNA Methylation | DNA Modification Methylases - genetics | Glioblastoma - genetics | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Female | Aged | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Index Medicus | Original Reports | Neur7 | Neur1
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2015, Volume 17, Issue suppl 5, pp. v107.1 - v107
Journal Article
6.
Full Text
Four-Year Weight Losses in the Look AHEAD Study: Factors Associated With Long-Term Success
Obesity, ISSN 1930-7381, 10/2011, Volume 19, Issue 10, pp. 1987 - 1998
This report provides a further analysis of the year 4 weight losses in the Look AHEAD (Action for Health in Diabetes) study and identifies factors associated...
LIFE-STYLE INTERVENTION | OBESITY | NUTRITION & DIETETICS | MANAGEMENT | COMMUNITY | ENDOCRINOLOGY & METABOLISM | LOSS MAINTENANCE | RISK | PHYSICAL-ACTIVITY | BEHAVIORAL TREATMENT | DIABETES-PREVENTION-PROGRAM | ACTIVITY GOALS | Life Style | Obesity - complications | Humans | Middle Aged | Male | Treatment Outcome | Energy Intake | Weight Reduction Programs | Group Processes | Exercise | Diet | Weight Loss | Obesity - therapy | Female | Diabetes Mellitus, Type 2 - complications | Health Education | Intervention | Obesity | Weight control | Lifestyles | Diabetes | Long term | Success | weight loss | prediction | lifestyle modification | weight maintenance
LIFE-STYLE INTERVENTION | OBESITY | NUTRITION & DIETETICS | MANAGEMENT | COMMUNITY | ENDOCRINOLOGY & METABOLISM | LOSS MAINTENANCE | RISK | PHYSICAL-ACTIVITY | BEHAVIORAL TREATMENT | DIABETES-PREVENTION-PROGRAM | ACTIVITY GOALS | Life Style | Obesity - complications | Humans | Middle Aged | Male | Treatment Outcome | Energy Intake | Weight Reduction Programs | Group Processes | Exercise | Diet | Weight Loss | Obesity - therapy | Female | Diabetes Mellitus, Type 2 - complications | Health Education | Intervention | Obesity | Weight control | Lifestyles | Diabetes | Long term | Success | weight loss | prediction | lifestyle modification | weight maintenance
Journal Article
7.
Full Text
Benefits and Challenges of Early Introduction of Left Ventricular Assist Device Placement
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 66, Issue 16, pp. 1762 - 1765
Rather, we advocate for a more nuanced interpretation of the findings: LVAD placement is a highly preference-sensitive decision; it involves a number of...
Cardiovascular | Internal Medicine | Medical ethics | Caregivers | Candidates | Hospitals | Illnesses | Decision making | Mortality
Cardiovascular | Internal Medicine | Medical ethics | Caregivers | Candidates | Hospitals | Illnesses | Decision making | Mortality
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Rindopepimut (also known as CDX-110), a vaccine targeting the deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet...
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 12/2018, Volume 140, Issue 3, pp. 727 - 737
To study the repeatability of plasma volume (v ) extracted from dynamic-contrast-enhanced (DCE) MRI in order to define threshold values for significant...
Least detected changes (LDD) | DCE-MRI | Earth mover’s distance (EMD) | Plasma volume (v | High grade brain tumors | Brain - diagnostic imaging | Reproducibility of Results | Image Enhancement | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Brain Neoplasms - pathology | Magnetic Resonance Imaging - methods | Male | Contrast Media | Brain - pathology | Adult | Female | Aged | Longitudinal Studies | Magnetic resonance imaging | Glioma | Brain tumors | Brain cancer | Bevacizumab
Least detected changes (LDD) | DCE-MRI | Earth mover’s distance (EMD) | Plasma volume (v | High grade brain tumors | Brain - diagnostic imaging | Reproducibility of Results | Image Enhancement | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Brain Neoplasms - pathology | Magnetic Resonance Imaging - methods | Male | Contrast Media | Brain - pathology | Adult | Female | Aged | Longitudinal Studies | Magnetic resonance imaging | Glioma | Brain tumors | Brain cancer | Bevacizumab
Journal Article
JAMA, ISSN 0098-7484, 07/2002, Volume 288, Issue 1, pp. 49 - 57
CONTEXT The Heart and Estrogen/progestin Replacement Study (HERS) found no overall reduction in risk of coronary heart disease (CHD) events among...
STROKE | MEDICINE, GENERAL & INTERNAL | ESTROGEN-REPLACEMENT | EVENTS | MYOCARDIAL-INFARCTION | INITIATION | RISK | PROGESTIN | POSTMENOPAUSAL WOMEN | RANDOMIZED TRIAL | Estrogen Replacement Therapy | Myocardial Infarction - epidemiology | Follow-Up Studies | Humans | Risk Factors | Medroxyprogesterone Acetate - therapeutic use | Coronary Disease - epidemiology | Treatment Outcome | Estrogens, Conjugated (USP) - therapeutic use | Coronary Disease - prevention & control | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Survival Analysis | Postmenopause | Female | Aged | Aspirin - therapeutic use | Prevention | Hormone therapy | Health aspects | Heart attack | Cardiovascular disease | Hormone replacement therapy | Health risk assessment | Clinical outcomes
STROKE | MEDICINE, GENERAL & INTERNAL | ESTROGEN-REPLACEMENT | EVENTS | MYOCARDIAL-INFARCTION | INITIATION | RISK | PROGESTIN | POSTMENOPAUSAL WOMEN | RANDOMIZED TRIAL | Estrogen Replacement Therapy | Myocardial Infarction - epidemiology | Follow-Up Studies | Humans | Risk Factors | Medroxyprogesterone Acetate - therapeutic use | Coronary Disease - epidemiology | Treatment Outcome | Estrogens, Conjugated (USP) - therapeutic use | Coronary Disease - prevention & control | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Survival Analysis | Postmenopause | Female | Aged | Aspirin - therapeutic use | Prevention | Hormone therapy | Health aspects | Heart attack | Cardiovascular disease | Hormone replacement therapy | Health risk assessment | Clinical outcomes
Journal Article
11.
Full Text
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
Journal of Neuro-Oncology, ISSN 0167-594X, 09/2016, Volume 129, Issue 3, pp. 453 - 460
Patients with progressive primary brain tumors (PBT) are attracted to promising new treatments, even prior to convincing data. Anti-PD1 immunotherapies have...
Pembrolizumab | Anti-PD1 | Primary brain tumor | Immunotherapy | Glioblastoma | CHEMOTHERAPY | CLINICAL NEUROLOGY | CELL LUNG-CANCER | UNTREATED MELANOMA | ONCOLOGY | PHASE-3 TRIAL | TEMOZOLOMIDE TREATMENT | HIGH-GRADE GLIOMAS | NIVOLUMAB | BLOCKADE | MISMATCH REPAIR DEFICIENCY | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Child, Preschool | Male | Treatment Outcome | Magnetic Resonance Imaging | Antineoplastic Agents, Immunological - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Adult | Female | Aged | Central Nervous System Neoplasms - drug therapy | Child | Cohort Studies | Antimitotic agents | Gliomas | Analysis | Brain tumors | Melanoma | Central nervous system | Metastasis | Antineoplastic agents
Pembrolizumab | Anti-PD1 | Primary brain tumor | Immunotherapy | Glioblastoma | CHEMOTHERAPY | CLINICAL NEUROLOGY | CELL LUNG-CANCER | UNTREATED MELANOMA | ONCOLOGY | PHASE-3 TRIAL | TEMOZOLOMIDE TREATMENT | HIGH-GRADE GLIOMAS | NIVOLUMAB | BLOCKADE | MISMATCH REPAIR DEFICIENCY | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Child, Preschool | Male | Treatment Outcome | Magnetic Resonance Imaging | Antineoplastic Agents, Immunological - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Adult | Female | Aged | Central Nervous System Neoplasms - drug therapy | Child | Cohort Studies | Antimitotic agents | Gliomas | Analysis | Brain tumors | Melanoma | Central nervous system | Metastasis | Antineoplastic agents
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 05/2018, Volume 137, Issue 3, pp. 601 - 609
Immune checkpoint inhibitors (ICPIs) have recently emerged as a novel treatment for cancer. These agents, transforming the field of oncology, are not devoid of...
CTLA-4 | Immune checkpoint inhibitors | PD-1 | Neurological complications | CANCER | CLINICAL NEUROLOGY | MELANOMA | THERAPY | ONCOLOGY | ENCEPHALITIS | MYASTHENIA-GRAVIS | NIVOLUMAB | ADVERSE EVENTS | IPILIMUMAB | Medicine, Experimental | Medical research | Cell death | Polyradiculitis | Corticoids | Encephalitis | Toxicity | Blocking antibodies | Cytotoxicity | Nervous system | Polyneuropathy | Meningoencephalitis | Immune checkpoint | Myositis | Apoptosis | Cancer | Index Medicus
CTLA-4 | Immune checkpoint inhibitors | PD-1 | Neurological complications | CANCER | CLINICAL NEUROLOGY | MELANOMA | THERAPY | ONCOLOGY | ENCEPHALITIS | MYASTHENIA-GRAVIS | NIVOLUMAB | ADVERSE EVENTS | IPILIMUMAB | Medicine, Experimental | Medical research | Cell death | Polyradiculitis | Corticoids | Encephalitis | Toxicity | Blocking antibodies | Cytotoxicity | Nervous system | Polyneuropathy | Meningoencephalitis | Immune checkpoint | Myositis | Apoptosis | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 05/2008, Volume 112, Issue 10, pp. 2267 - 2273
BACKGROUND Response rates to second‐line chemotherapy in recurrent high‐grade glial tumors are low and new effective treatments are needed. The objective of...
high‐grade gliomas | toxicity | bevacizumab | glioblastoma | irinotecan | Irinotecan | Toxicity | High-grade gliomas | Glioblastoma | Bevacizumab | LEUCOVORIN | PLUS IRINOTECAN | RANDOMIZED-TRIAL | FLUOROURACIL | CANCER
high‐grade gliomas | toxicity | bevacizumab | glioblastoma | irinotecan | Irinotecan | Toxicity | High-grade gliomas | Glioblastoma | Bevacizumab | LEUCOVORIN | PLUS IRINOTECAN | RANDOMIZED-TRIAL | FLUOROURACIL | CANCER